CMV regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of cisplatin , methotrexate,and vinblastine used to treat advanced..." |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}}MCV; CMV | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[cisplatin]] , [[methotrexate]],and [[vinblastine]] used to treat advanced [[bladder carcinoma]].<ref name="pmid8448083">{{cite journal| author=Paz-Ares L, Lianes P, Díaz-Puente M, Rivera F, Passas J, Costas P et al.| title=CMV front-line chemotherapy in transitional bladder carcinoma. | journal=Ann Oncol | year= 1993 | volume= 4 | issue= 2 | pages= 147-50 | pmid=8448083 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8448083 }} </ref> | |||
==Regimen== | |||
{{Chemo|C|Cisplatin}} | {{Chemo|C|Cisplatin}} | ||
{{chemo|M|Methotrexate}} | {{chemo|M|Methotrexate}} | ||
{{chemo|V|Vinblastine}} | {{chemo|V|Vinblastine}} | ||
==Indications== | ==Indications== | ||
*Transitional [[bladder carcinoma]].<ref name="pmid8448083">{{cite journal| author=Paz-Ares L, Lianes P, Díaz-Puente M, Rivera F, Passas J, Costas P et al.| title=CMV front-line chemotherapy in transitional bladder carcinoma. | journal=Ann Oncol | year= 1993 | volume= 4 | issue= 2 | pages= 147-50 | pmid=8448083 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8448083 }} </ref> | *Transitional [[bladder carcinoma]].<ref name="pmid8448083">{{cite journal| author=Paz-Ares L, Lianes P, Díaz-Puente M, Rivera F, Passas J, Costas P et al.| title=CMV front-line chemotherapy in transitional bladder carcinoma. | journal=Ann Oncol | year= 1993 | volume= 4 | issue= 2 | pages= 147-50 | pmid=8448083 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8448083 }} </ref> | ||
Latest revision as of 17:40, 11 March 2015
|
WikiDoc Resources for CMV regimen |
|
Articles |
|---|
|
Most recent articles on CMV regimen Most cited articles on CMV regimen |
|
Media |
|
Powerpoint slides on CMV regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CMV regimen at Clinical Trials.gov Clinical Trials on CMV regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CMV regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CMV regimen Discussion groups on CMV regimen Patient Handouts on CMV regimen Directions to Hospitals Treating CMV regimen Risk calculators and risk factors for CMV regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CMV regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:MCV; CMV
Overview
CMV regimen refers to a regimen consisting of cisplatin , methotrexate,and vinblastine used to treat advanced bladder carcinoma.[1]
Regimen
CCisplatin
MMethotrexate
VVinblastine
Indications
- Transitional bladder carcinoma.[1]
References
- ↑ 1.0 1.1 Paz-Ares L, Lianes P, Díaz-Puente M, Rivera F, Passas J, Costas P; et al. (1993). "CMV front-line chemotherapy in transitional bladder carcinoma". Ann Oncol. 4 (2): 147–50. PMID 8448083.